Drugs that contain Roflumilast
1. Daliresp patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9468598 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb, 2023
(1 year, 2 months ago) | |
| US8431154 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb, 2023
(1 year, 2 months ago) | |
| US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) | |
| US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) | |
| US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-208) | Aug 31, 2020 |
| New Strength(NS) | Jan 23, 2021 |
| New Dosing Schedule(D-171) | Jan 23, 2021 |
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2016 |
NCE-1 date: 28 February, 2015
Market Authorisation Date: 23 January, 2018
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
Dosage: TABLET;ORAL
DALIRESP family patents
2. Zoryve patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9884050 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US9907788 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US11819496 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half-life |
Jun, 2037
(13 years from now) | |
| US10940142 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US11793796 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US11129818 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half life |
Aug, 2037
(13 years from now) | |
| US11707454 | ARCUTIS | Topical roflumilast formulation having antifungal properties |
Dec, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 05, 2026 |
| New Product(NP) | Jul 29, 2025 |
Market Authorisation Date: 29 July, 2022
Treatment: Topical treatment of seborrheic dermatitis in patients 9 years of age and older; Topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. (1)
Dosage: FOAM;TOPICAL
ZORYVE family patents